TAKEDA today announced that the US Food and Drug Administration has approved HyQvia for the treatment of chronic inflammatory demyelinating polyneuropathy as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults, with approval based on the phase 3 ADVANCE-CIDP 1 Study.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Jan 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Jan 24
